{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:29:41Z","timestamp":1794274181917,"version":"4.9.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.beha.2023.101514","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T03:23:52Z","timestamp":1696649032000},"page":"101514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment"],"prefix":"10.1016","volume":"36","author":[{"given":"Rebecca","family":"Masel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1483-4551","authenticated-orcid":false,"given":"Ubaldo","family":"Martinez-Outschoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2023.101514_bib1","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2023.101514_bib2","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/ajh.26717","article-title":"Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management","volume":"97","author":"Ansell","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-019-0799-1","article-title":"Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study","volume":"12","author":"Zhou","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.beha.2023.101514_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.seminoncol.2014.02.005","article-title":"Tumor macroenvironment and metabolism","volume":"41","author":"Al-Zoughbi","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.beha.2023.101514_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/bs.acr.2015.04.011","article-title":"The tumor macroenvironment: cancer-promoting networks beyond tumor beds","volume":"128","author":"Rutkowski","year":"2015","journal-title":"Adv Cancer Res"},{"issue":"2","key":"10.1016\/j.beha.2023.101514_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000502097","article-title":"Tumor macroenvironment: an update","volume":"87","author":"Al-Zoughbi","year":"2020","journal-title":"Pathobiology"},{"key":"10.1016\/j.beha.2023.101514_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103676","article-title":"Paraneoplastic syndromes review: the great forgotten ones","volume":"174","author":"Sardina Gonzalez","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"27","key":"10.1016\/j.beha.2023.101514_bib8","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2023.101514_bib9","first-page":"116","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.beha.2023.101514_bib10","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00277-020-04093-4","article-title":"Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis-a dangerous disease","volume":"99","author":"Jin","year":"2020","journal-title":"Ann Hematol"},{"issue":"23","key":"10.1016\/j.beha.2023.101514_bib11","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Rosee","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2023.101514_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102416","article-title":"Formation of the immunosuppressive microenvironment of classic hodgkin lymphoma and therapeutic approaches to counter it","volume":"20","author":"Aldinucci","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.2711","article-title":"The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape","volume":"221","author":"Aldinucci","year":"2010","journal-title":"J Pathol"},{"issue":"14","key":"10.1016\/j.beha.2023.101514_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143634","article-title":"Immune microenvironment features and dynamics in hodgkin lymphoma","volume":"13","author":"Bertuzzi","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.seminoncol.2017.10.003","article-title":"Hodgkin lymphoma: a complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment","volume":"44","author":"Mikkilineni","year":"2017","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2023.101514_bib16","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1172\/JCI95993","article-title":"Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells","volume":"128","author":"Weniger","year":"2018","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.beha.2023.101514_bib17","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.2353\/ajpath.2010.100089","article-title":"Tumorigenic potential of mononucleated small cells of Hodgkin lymphoma cell lines","volume":"177","author":"Ikeda","year":"2010","journal-title":"Am J Pathol"},{"issue":"23","key":"10.1016\/j.beha.2023.101514_bib18","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"Kuppers","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-019-0195-7","article-title":"Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma","volume":"9","author":"Mata","year":"2019","journal-title":"Blood Cancer J"},{"issue":"23","key":"10.1016\/j.beha.2023.101514_bib20","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.beha.2023.101514_bib21","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Campo","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2023.101514_bib22","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.beha.2023.101514_bib23","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2023.101514_bib25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-021-00518-z","article-title":"Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies","volume":"11","author":"Mohty","year":"2021","journal-title":"Blood Cancer J"},{"issue":"27","key":"10.1016\/j.beha.2023.101514_bib26","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2023.101514_bib27","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2014-07-537480","article-title":"Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma","volume":"125","author":"Connors","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/ejh.12583","article-title":"Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome","volume":"96","author":"Andersen","year":"2016","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2023.101514_bib29","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ijc.23119","article-title":"Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5\/Rantes in tumor cell growth and microenvironmental interactions","volume":"122","author":"Aldinucci","year":"2008","journal-title":"Int J Cancer"},{"issue":"19","key":"10.1016\/j.beha.2023.101514_bib30","first-page":"2343","article-title":"Spatial and molecular profiling of the mononuclear phagocyte network in classic Hodgkin lymphoma","volume":"141","author":"Stewart","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101514_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122121","article-title":"Targeting tumour-associated macrophages in hodgkin lymphoma using engineered extracellular matrix-mimicking cryogels","volume":"297","author":"Bahlmann","year":"2023","journal-title":"Biomaterials"},{"issue":"13","key":"10.1016\/j.beha.2023.101514_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136995","article-title":"Macrophage polarization states in the tumor microenvironment","volume":"22","author":"Boutilier","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.beha.2023.101514_bib33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101514_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1746-1596-7-12","article-title":"CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma","volume":"7","author":"Harris","year":"2012","journal-title":"Diagn Pathol"},{"issue":"16","key":"10.1016\/j.beha.2023.101514_bib35","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2012-04-421057","article-title":"Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial","volume":"120","author":"Tan","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.878","article-title":"Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma","volume":"27","author":"Schreck","year":"2009","journal-title":"Hematol Oncol"},{"issue":"21","key":"10.1016\/j.beha.2023.101514_bib37","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood.2020005546","article-title":"Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58","volume":"136","author":"Veldman","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2023.101514_bib38","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.beha.2023.101514_bib39","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.132761","article-title":"The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints","volume":"101","author":"Vardhana","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2023.101514_bib40","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","article-title":"High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma","volume":"154","author":"van den Berg","year":"1999","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.beha.2023.101514_bib41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.23361","article-title":"Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma","volume":"88","author":"Sauer","year":"2013","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.beha.2023.101514_bib42","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2023019661","article-title":"Increasing microenvironment complexity in HL","volume":"141","author":"Chabay","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2023.101514_bib43","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2326-6066.CIR-17-0325","article-title":"Complex immune evasion strategies in classical hodgkin lymphoma","volume":"5","author":"Wein","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.beha.2023.101514_bib44","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/modpathol.2009.54","article-title":"Lymphocyte-rich classical Hodgkin's lymphoma: distinctive tumor and microenvironment markers","volume":"22","author":"Nam-Cha","year":"2009","journal-title":"Mod Pathol"},{"issue":"15","key":"10.1016\/j.beha.2023.101514_bib45","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood.2022017147","article-title":"Novel insights into Hodgkin lymphoma biology by single-cell analysis","volume":"141","author":"Aoki","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2023.101514_bib46","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.humpath.2013.06.006","article-title":"B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction","volume":"44","author":"Tudor","year":"2013","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/blood.V97.1.250","article-title":"Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"97","author":"Skinnider","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101514_bib49","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3389\/fimmu.2018.01358","article-title":"Hodgkin lymphoma-derived extracellular vesicles change the secretome of fibroblasts toward a CAF phenotype","volume":"9","author":"Dorsam","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.beha.2023.101514_bib50","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0394632016644447","article-title":"Role of mast cells in fibrosis of classical Hodgkin lymphoma","volume":"29","author":"Nakayama","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.beha.2023.101514_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.964573","article-title":"Inflammatory microenvironment in classical Hodgkin's lymphoma with special stress on mast cells","volume":"12","author":"Ribatti","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.beha.2023.101514_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102803","article-title":"The tumor microenvironment in classic Hodgkin's lymphoma in responder and No-responder patients to first line ABVD therapy","volume":"15","author":"Tamma","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.beha.2023.101514_bib53","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/bloodadvances.2020003664","article-title":"Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma","volume":"5","author":"Gholiha","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.beha.2023.101514_bib54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/BMM.15.30","article-title":"Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma","volume":"9","author":"Carlo-Stella","year":"2015","journal-title":"Biomark Med"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2141.2002.03575.x","article-title":"Interleukin 6 expression by Hodgkin\/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease","volume":"118","author":"Reynolds","year":"2002","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.beha.2023.101514_bib56","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1158\/1078-0432.CCR-08-1026","article-title":"Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma","volume":"14","author":"Biggar","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjh.17116","article-title":"SARS-CoV-2-induced remission of Hodgkin lymphoma","volume":"192","author":"Challenor","year":"2021","journal-title":"Br J Haematol"},{"issue":"7\u20138","key":"10.1016\/j.beha.2023.101514_bib58","article-title":"SARS-CoV-2-induced remission of advanced classical Hodgkin lymphoma","volume":"132","author":"Kurlapski","year":"2022","journal-title":"Pol Arch Intern Med"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V75.1.13.13","article-title":"Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia","volume":"75","author":"Samoszuk","year":"1990","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2023.101514_bib60","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2023.101514_bib61","first-page":"1229","article-title":"Interleukin-8 in Hodgkin's disease. Preferential expression by reactive cells and association with neutrophil density","volume":"148","author":"Foss","year":"1996","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.beha.2023.101514_bib62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/path.4306","article-title":"Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma","volume":"232","author":"Hansen","year":"2014","journal-title":"J Pathol"},{"issue":"7","key":"10.1016\/j.beha.2023.101514_bib63","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.V87.7.2918.bloodjournal8772918","article-title":"Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease","volume":"87","author":"Herbst","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJM198101153040302","article-title":"Childhood social environment and Hodgkin's disease","volume":"304","author":"Gutensohn","year":"1981","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2023.101514_bib65","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/(SICI)1097-0215(19970917)72:6<977::AID-IJC10>3.0.CO;2-2","article-title":"Birth order, sibship size and risk of Hodgkin's disease in children and young adults: a population-based study of 31 million person-years","volume":"72","author":"Westergaard","year":"1997","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.beha.2023.101514_bib66","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1055-9965.EPI-04-0567","article-title":"Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California","volume":"14","author":"Clarke","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.beha.2023.101514_bib67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/cei.12716","article-title":"The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma","volume":"183","author":"Jones","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"20","key":"10.1016\/j.beha.2023.101514_bib68","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1182\/bloodadvances.2021005304","article-title":"Adoptive T-cell therapy for Hodgkin lymphoma","volume":"5","author":"Ho","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.beha.2023.101514_bib69","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2023.101514_bib70","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2023.101514_bib71","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/ijc.30473","article-title":"The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis","volume":"140","author":"Carbone","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.beha.2023.101514_bib72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2016.05.001","article-title":"NF-kappaB deregulation in Hodgkin lymphoma","volume":"39","author":"Weniger","year":"2016","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib73","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2018-02-833806","article-title":"Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?","volume":"132","author":"Carbone","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2023.101514_bib74","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101514_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1203470","article-title":"Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin\/Reed-Sternberg cells","volume":"13","author":"Cellini","year":"2023","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.beha.2023.101514_bib76","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","article-title":"Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy","volume":"103","author":"de Charette","year":"2018","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.beha.2023.101514_bib77","first-page":"2187","article-title":"Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma","volume":"141","author":"Carbone","year":"2023","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2023.101514_bib78","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2023.101514_bib79","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2023.101514_bib80","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2023.101514_bib81","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib82","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2023.101514_bib83","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2023.101514_bib84","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib85","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov"},{"issue":"21","key":"10.1016\/j.beha.2023.101514_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215487","article-title":"CD8+ T lymphocytes immune depletion and LAG-3 overexpression in hodgkin lymphoma tumor microenvironment exposed to anti-PD-1 immunotherapy","volume":"13","author":"Michot","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib87","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-065X.2011.01064.x","article-title":"The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation","volume":"244","author":"Steinberg","year":"2011","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.beha.2023.101514_bib88","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/bjh.18137","article-title":"Checkpoint CD47 expression in classical Hodgkin lymphoma","volume":"197","author":"Gholiha","year":"2022","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2023.101514_bib89","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bjc.2013.60","article-title":"Fecal microbiota diversity in survivors of adolescent\/young adult Hodgkin lymphoma: a study of twins","volume":"108","author":"Cozen","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib90","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/leu.2017.203","article-title":"An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma","volume":"32","author":"Lollies","year":"2018","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.beha.2023.101514_bib91","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib92","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib93","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CLM.2004.n.007","article-title":"Paraneoplastic manifestations of lymphoma","volume":"5","author":"Hagler","year":"2004","journal-title":"Clin Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2023.101514_bib94","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/PPO.0b013e3181a282d8","article-title":"Clinical manifestations and natural history of Hodgkin's lymphoma","volume":"15","author":"Connors","year":"2009","journal-title":"Cancer J"},{"issue":"13","key":"10.1016\/j.beha.2023.101514_bib95","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2006.08.1331","article-title":"Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"25","author":"Casasnovas","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2023.101514_bib96","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-114-5-361","article-title":"Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group","volume":"114","author":"Henry-Amar","year":"1991","journal-title":"Ann Intern Med"},{"issue":"15","key":"10.1016\/j.beha.2023.101514_bib97","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2009.27.6873","article-title":"Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin","volume":"28","author":"Hohaus","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5\u20136","key":"10.1016\/j.beha.2023.101514_bib98","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/10428199909058479","article-title":"Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease","volume":"34","author":"Ayoub","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2023.101514_bib99","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beha.2023.101514_bib100","article-title":"Paraneoplastic syndromes associated with classic Hodgkin lymphoma, a systematic literature review","author":"El Fakih","year":"2023","journal-title":"Ann Hematol"},{"issue":"21","key":"10.1016\/j.beha.2023.101514_bib101","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood-2014-03-537506","article-title":"Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas","volume":"123","author":"Graus","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2023.101514_bib102","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/01.WNL.0000041495.87539.98","article-title":"Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease","volume":"60","author":"Bernal","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib103","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ncl.2018.04.015","article-title":"Paraneoplastic neurologic syndromes","volume":"36","author":"Rosenfeld","year":"2018","journal-title":"Neurol Clin"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib104","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.08.029","article-title":"Granulomatous angiitis of the central nervous system associated with Hodgkin's lymphoma: case report and literature review","volume":"27","author":"Lopez-Chiriboga","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.beha.2023.101514_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-224961","article-title":"Paraneoplastic granulomatous dermatitis in a patient with Hodgkin's disease: a diagnostic pitfall","volume":"2018","author":"Tabata","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.beha.2023.101514_bib106","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00296-002-0229-4","article-title":"Malignant lymphoma-associated autoimmune diseases--a descriptive epidemiological study","volume":"22","author":"Varoczy","year":"2002","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.beha.2023.101514_bib107","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4137\/CCRep.S5243","article-title":"Sarcoid reactions after chemotherapy for Hodgkin's lymphoma","volume":"3","author":"Wirk","year":"2010","journal-title":"Clin Med Insights Case Rep"},{"issue":"7","key":"10.1016\/j.beha.2023.101514_bib108","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.crad.2009.03.005","article-title":"Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET\/CT: prevalence and disease pattern","volume":"64","author":"Chowdhury","year":"2009","journal-title":"Clin Radiol"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib109","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11899-012-0131-4","article-title":"Recognizing unusual manifestations of Hodgkin lymphoma","volume":"7","author":"Barber","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"10.1016\/j.beha.2023.101514_bib110","article-title":"Characterization of the microenvironment of nodular lymphocyte predominant hodgkin lymphoma","volume":"17","author":"Visser","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib111","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.18376","article-title":"Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma","volume":"199","author":"Hartmann","year":"2022","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.beha.2023.101514_bib112","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2023.101514_bib113","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","article-title":"The molecular pathogenesis of primary mediastinal large B-cell lymphoma","volume":"118","author":"Steidl","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib114","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11899-011-0090-1","article-title":"Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?","volume":"6","author":"Grant","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13000-019-0918-x","article-title":"Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma","volume":"14","author":"Kim","year":"2019","journal-title":"Diagn Pathol"},{"issue":"34","key":"10.1016\/j.beha.2023.101514_bib116","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.beha.2023.101514_bib117","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.ejca.2011.06.029","article-title":"Body mass index and risk of non-Hodgkin's and Hodgkin's lymphoma: a meta-analysis of prospective studies","volume":"47","author":"Larsson","year":"2011","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.beha.2023.101514_bib118","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41416-019-0401-1","article-title":"Body mass index and Hodgkin's lymphoma: UK population-based cohort study of 5.8 million individuals","volume":"120","author":"Strongman","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib119","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","article-title":"Cancer metabolism: a therapeutic perspective","volume":"14","author":"Martinez-Outschoorn","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2023.101514_bib120","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/ijc.29934","article-title":"Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma are highly dependent on oxidative phosphorylation","volume":"138","author":"Birkenmeier","year":"2016","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib121","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.beha.2023.101514_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065141","article-title":"Prognostic value of monocarboxylate transporter 1 overexpression in cancer: a systematic review","volume":"24","author":"Silva","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib123","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1053\/j.seminoncol.2017.10.002","article-title":"Mitochondrial and glycolytic metabolic compartmentalization in diffuse large B-cell lymphoma","volume":"44","author":"Gooptu","year":"2017","journal-title":"Semin Oncol"},{"issue":"51","key":"10.1016\/j.beha.2023.101514_bib124","doi-asserted-by":"crossref","first-page":"26291","DOI":"10.1074\/jbc.M116.740209","article-title":"TP53-inducible glycolysis and apoptosis regulator (TIGAR) metabolically reprograms carcinoma and stromal cells in breast cancer","volume":"291","author":"Ko","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2023.101514_bib125","series-title":"TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer","author":"Roche","year":"2023"},{"issue":"12","key":"10.1016\/j.beha.2023.101514_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165962","article-title":"Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma","volume":"1866","author":"Roche","year":"2020","journal-title":"Biochim Biophys Acta, Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.beha.2023.101514_bib127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","article-title":"18)F-FDG avidity in lymphoma readdressed: a study of 766 patients","volume":"51","author":"Weiler-Sagie","year":"2010","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.beha.2023.101514_bib128","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","article-title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study","volume":"3","author":"Agostinelli","year":"2016","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.beha.2023.101514_bib129","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.beha.2023.101514_bib130","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.beha.2023.101514_bib131","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1182\/blood-2012-03-403790","article-title":"Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?","volume":"120","author":"Gallamini","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101514_bib132","doi-asserted-by":"crossref","first-page":"9213","DOI":"10.1182\/blood-2022-166120","article-title":"Tumor microenvironment composition correlates with quantitative 18F-FDG PET-CT features and serum TARC in patients with relapsed or refractory hodgkin lymphoma","volume":"140","author":"Driessen","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2023.101514_bib133","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2001.03147.x","article-title":"Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma","volume":"115","author":"Naumann","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2023.101514_bib134","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13441","article-title":"Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis","volume":"170","author":"Adams","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101514_bib135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2019.05.010","article-title":"Proportion of false-positive follow-up FDG-PET scans in lymphoma: systematic review and meta-analysis","volume":"141","author":"Adams","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.beha.2023.101514_bib136","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"issue":"21","key":"10.1016\/j.beha.2023.101514_bib137","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2023.101514_bib138","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1182\/blood.2023020326","article-title":"The next frontier: enter PD-1 and exit PET scans?","volume":"141","author":"Mei","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2023.101514_bib139","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.beha.2023.101514_bib140","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101514_bib141","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera Af","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.beha.2023.101514_bib142","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2023.101514_bib143","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.beha.2023.101514_bib144","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:09:36Z","timestamp":1761498576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692623000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":144,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1521692623000750"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101514","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101514"}}